Nabriva Therapeutics Past Earnings Performance
Past criteria checks 0/6
Nabriva Therapeutics has been growing earnings at an average annual rate of 18.5%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 39.4% per year.
Key information
18.5%
Earnings growth rate
60.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 39.4% |
| Return on equity | n/a |
| Net Margin | -186.3% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Nabriva Therapeutics to effect 1-for-25 reverse stock split
Sep 15Nabriva stock soars 19% on distribution deal with Er-Kim for bacterial pneumonia drug Xenleta
Jul 18Need To Know: The Consensus Just Cut Its Nabriva Therapeutics plc (NASDAQ:NBRV) Estimates For 2022
Apr 04
Bullish: Analysts Just Made A Noticeable Upgrade To Their Nabriva Therapeutics plc (NASDAQ:NBRV) Forecasts
Aug 11We Think Some Shareholders May Hesitate To Increase Nabriva Therapeutics plc's (NASDAQ:NBRV) CEO Compensation
Jul 22Nabriva Therapeutics plc 2021 Q1 - Results - Earnings Call Presentation
May 08When Will Nabriva Therapeutics plc (NASDAQ:NBRV) Breakeven?
Feb 16Nabriva Therapeutics announces proposed public offering
Dec 10Nabriva Therapeutics shares gain as Sinovant expands Xenleta support in China
Dec 07Nabriva Therapeutics plc 2020 Q3 - Results - Earnings Call Presentation
Nov 08Revenue & Expenses BreakdownBeta
How Nabriva Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 30 | -55 | 31 | 0 |
| 31 Mar 23 | 37 | -54 | 37 | 0 |
| 31 Dec 22 | 37 | -57 | 45 | 0 |
| 30 Sep 22 | 36 | -47 | 50 | 0 |
| 30 Jun 22 | 35 | -47 | 50 | 0 |
| 31 Mar 22 | 34 | -47 | 52 | 0 |
| 31 Dec 21 | 29 | -49 | 52 | 0 |
| 30 Sep 21 | 22 | -54 | 55 | 0 |
| 30 Jun 21 | 15 | -57 | 53 | 0 |
| 31 Mar 21 | 7 | -60 | 51 | 0 |
| 31 Dec 20 | 5 | -69 | 55 | 0 |
| 30 Sep 20 | 3 | -75 | 55 | 0 |
| 30 Jun 20 | 9 | -80 | 62 | 0 |
| 31 Mar 20 | 9 | -86 | 65 | 0 |
| 31 Dec 19 | 9 | -83 | 62 | 0 |
| 30 Sep 19 | 10 | -91 | 56 | 0 |
| 30 Jun 19 | 3 | -126 | 50 | 0 |
| 31 Mar 19 | 4 | -122 | 45 | 0 |
| 31 Dec 18 | 10 | -115 | 42 | 0 |
| 30 Sep 18 | 10 | -106 | 42 | 0 |
| 30 Jun 18 | 11 | -76 | 39 | 0 |
| 31 Mar 18 | 11 | -72 | 35 | 0 |
| 31 Dec 17 | 5 | -74 | 29 | 0 |
| 30 Sep 17 | 7 | -67 | 23 | 0 |
| 30 Jun 17 | 6 | -59 | 17 | 0 |
| 31 Mar 17 | 7 | -57 | 15 | 0 |
| 31 Dec 16 | 6 | -55 | 14 | 0 |
| 30 Sep 16 | 5 | -67 | 13 | -15 |
| 30 Jun 16 | 5 | -61 | 12 | -8 |
| 31 Mar 16 | 5 | -55 | 10 | -3 |
| 31 Dec 15 | 4 | -51 | 8 | 0 |
| 30 Sep 15 | 3 | -30 | 6 | 18 |
| 30 Jun 15 | 2 | -26 | 5 | 12 |
| 31 Mar 15 | 2 | -21 | 3 | 8 |
| 31 Dec 14 | 2 | -14 | 4 | 0 |
| 31 Dec 13 | 3 | 15 | 4 | 10 |
Quality Earnings: NBRV.F is currently unprofitable.
Growing Profit Margin: NBRV.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NBRV.F is unprofitable, but has reduced losses over the past 5 years at a rate of 18.5% per year.
Accelerating Growth: Unable to compare NBRV.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NBRV.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: NBRV.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.